SCHOTT Pharma jumps as DB ups to 'buy' on growth prospects

Stevanato SpA

06/07/2026 09:06

** Shares in SCHOTT Pharma 1SXP.DE rise 7.7% after Deutsche Bank upgraded the German medical equipment supplier to "buy" from "hold" on accelerating growth, improving margins
** DB expects growth to speed up in Q3 and Q4, after reduced demand from a key glass syringe customer weighed on H1
** DB sees FY targets as "achievable" at midpoint and expects organic sales growth of 6% to 8% and continued margin expansion from 2027 onwards 
** It expects the P/E ratio for 2027 to trade at a roughly 30% discount to Italian peer Stevanato STVN.N
** Stock, which is on track for its best day since May 2025, tops Germany's small-cap index .SDAXI
** Out of 13 analysts covering SCHOTT Pharma, eight rate it "strong buy" or "buy", ​four "hold" and one "sell" – LSEG data

(Reporting by Danny Callaghan)
((danny.callaghan@thomsonreuters.com))